Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO(2) ≤ 96% despite O(2)-support ≥ 6 L/min) without invasive mechanical ventilation wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Benjamin, Nguyen, Lee S., Zimmermann, Philippe, Boucenna, Faiza, Dubret, Louis, Baucher, Louise, Guillot, Helene, Bouldouyre, Marie-Anne, Allenbach, Yves, Salem, Joe-Elie, Barsoum, Paul, Oufella, Arezki, Gros, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603074/
https://www.ncbi.nlm.nih.gov/pubmed/33080877
http://dx.doi.org/10.3390/ph13100317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603074/
https://www.ncbi.nlm.nih.gov/pubmed/33080877
http://dx.doi.org/10.3390/ph13100317

Ejemplares similares